AE	Adverse Event
AEG	Adenocarcinoma of the Esophagogastric Junction
CAFs	Cancer-Associated Fibroblasts
CAR	Chimeric Antigen Receptor
CEA	Carcinoembryonic Antigen
CPS	Combined Positive Score
CRC	Colorectal Cancer
CTLA-4	Cytotoxic T-Lymphocyte Antigen 4
CXCR4	C-X-C Chemokine Receptor 4
dMMR	Deficient DNA Mismatch Repair
DDR	DNA Damage Response
DOR	Duration of Response
EGFR	Epidermal Growth Factor Receptor
FDA	Food and Drug Administration
FGFR	Fibroblast Growth Factor Receptor
FMT	Fecal Microbiota Transplantation
FOLFOX	Leucovorin, 5-Fluorouracil, Oxaliplatin
GC	Gastric Cancer
GEJ	Gastroesophageal Junction
HCC	Hepatocellular Carcinoma
HER2	Human Epidermal Growth Factor Receptor 2
HR	Hazard Ratio
ICI	Immune Checkpoint Inhibitor
ICB	Immune Checkpoint Blockade
IL-10	Interleukin 10
KRAS	Kirsten Rat Sarcoma Viral Oncogene
LAG-3	Lymphocyte Activation Gene 3
MAPK	Mitogen-Activated Protein Kinase
MDSCs	Myeloid-Derived Suppressor Cells
MSS	Microsatellite Stable
MSI-H	Microsatellite Instability-High
mRNA	Messenger RNA
NCT	Neoadjuvant Chemotherapy
ORR	Objective Response Rate
OS	Overall Survival
PARP	Poly (ADP-Ribose) Polymerase
PD-1	Programmed Death 1
PD-L1	Programmed Death Ligand 1
PD-L2	Programmed Death Ligand 2
PDAC	Pancreatic Ductal Adenocarcinoma
PFS	Progression-Free Survival
PSCA	Prostate Stem Cell Antigen
STRIDE	Single Tremelimumab Regular Interval Durvalumab
TGF-β	Transforming Growth Factor Beta
TIL	Tumor-Infiltrating Lymphocyte
TKI	Tyrosine Kinase Inhibitor
TMB	Tumor Mutational Burden
TME	Tumor Microenvironment
TRAEs	Treatment-Related Adverse Events
VEGF	Vascular Endothelial Growth Factor
XELOX	Capecitabine, Oxaliplatin